145 related articles for article (PubMed ID: 20092958)
1. Survey of British pathologists' performance of mesothelioma post-mortems.
Goldstein R; Hasleton PS
Pathol Res Pract; 2010 Mar; 206(3):174-9. PubMed ID: 20092958
[TBL] [Abstract][Full Text] [Related]
2. Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
Ascoli V; Minelli G; Cozzi I; Romeo E; Carnovale Scalzo C; Ancona L; Forastiere F
Pathol Res Pract; 2016 Oct; 212(10):886-892. PubMed ID: 27485167
[TBL] [Abstract][Full Text] [Related]
3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.
Linton A; Kao S; Vardy J; Clarke S; van Zandwijk N; Klebe S
Asia Pac J Clin Oncol; 2013 Sep; 9(3):273-9. PubMed ID: 23167246
[TBL] [Abstract][Full Text] [Related]
5. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
6. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Husain AN; Colby TV; Ordóñez NG; Allen TC; Attanoos RL; Beasley MB; Butnor KJ; Chirieac LR; Churg AM; Dacic S; Galateau-Sallé F; Gibbs A; Gown AM; Krausz T; Litzky LA; Marchevsky A; Nicholson AG; Roggli VL; Sharma AK; Travis WD; Walts AE; Wick MR
Arch Pathol Lab Med; 2018 Jan; 142(1):89-108. PubMed ID: 28686500
[TBL] [Abstract][Full Text] [Related]
8. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
9. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Takeshima Y; Amatya VJ; Kushitani K; Kaneko M; Inai K
Histopathology; 2009 May; 54(6):667-76. PubMed ID: 19438742
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
11. How to assess the best immunohistochemical panel in the diagnosis of malignant pleural mesothelioma in a pathology lab.
Mlika M; Lamzibri O; Bacha S; Laabidi S; Haddouchi C; Mezni FE
J Immunoassay Immunochem; 2018; 39(3):263-273. PubMed ID: 29757709
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples.
Monaco S; Mehrad M; Dacic S
Adv Anat Pathol; 2018 Jan; 25(1):24-30. PubMed ID: 29227332
[TBL] [Abstract][Full Text] [Related]
13. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
Husain AN; Colby TV; Ordóñez NG; Krausz T; Borczuk A; Cagle PT; Chirieac LR; Churg A; Galateau-Salle F; Gibbs AR; Gown AM; Hammar SP; Litzky LA; Roggli VL; Travis WD; Wick MR
Arch Pathol Lab Med; 2009 Aug; 133(8):1317-31. PubMed ID: 19653732
[TBL] [Abstract][Full Text] [Related]
15. Malignant Mesothelioma Diagnosis.
Arif Q; Husain AN
Arch Pathol Lab Med; 2015 Aug; 139(8):978-80. PubMed ID: 26230591
[TBL] [Abstract][Full Text] [Related]
16. MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Amatya VJ; Kushitani K; Mawas AS; Miyata Y; Okada M; Kishimoto T; Inai K; Takeshima Y
Mod Pathol; 2017 May; 30(5):672-681. PubMed ID: 28128276
[TBL] [Abstract][Full Text] [Related]
17. Primary malignant pericardial sarcomatoid mesothelioma: An autopsy report.
Muta H; Sugita Y; Ohshima K; Otsubo H
Pathol Int; 2017 Jun; 67(6):311-315. PubMed ID: 28463437
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
Husain AN; Colby T; Ordonez N; Krausz T; Attanoos R; Beasley MB; Borczuk AC; Butnor K; Cagle PT; Chirieac LR; Churg A; Dacic S; Fraire A; Galateau-Salle F; Gibbs A; Gown A; Hammar S; Litzky L; Marchevsky AM; Nicholson AG; Roggli V; Travis WD; Wick M;
Arch Pathol Lab Med; 2013 May; 137(5):647-67. PubMed ID: 22929121
[TBL] [Abstract][Full Text] [Related]
19. [Sarcomatoid mesothelioma--a diagnostic challenge].
Eiholm S; Meyer CN; Behrendt N
Ugeskr Laeger; 2010 Sep; 172(39):2670-1. PubMed ID: 20920392
[TBL] [Abstract][Full Text] [Related]
20. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
